Buffa et al. described NFE2L2 as a predicted target of miR-144 [47] and observed that patients who had tumours with low miR-144 and high NFE2L2 mRNA, but also protein expression levels, had an improved distant relapse-free survival, whereas the opposite expression pattern was associated with a poor outcome. The gene discussed is NFE2L2; the disease is neoplasm.